IRIS - Res&Arch Institutional Research Information System - Research & Archive

FIORETTI, Maria Cristina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.424
EU - Europa 2.782
AS - Asia 2.600
SA - Sud America 530
Continente sconosciuto - Info sul continente non disponibili 194
AF - Africa 81
OC - Oceania 5
Totale 10.616
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.269
SG - Singapore 1.308
UA - Ucraina 588
IE - Irlanda 440
BR - Brasile 389
IT - Italia 344
CN - Cina 337
SE - Svezia 326
RU - Federazione Russa 316
HK - Hong Kong 296
VN - Vietnam 267
DE - Germania 230
FR - Francia 150
FI - Finlandia 149
GB - Regno Unito 80
KR - Corea 73
IN - India 72
BD - Bangladesh 64
CA - Canada 62
AR - Argentina 41
CO - Colombia 33
TR - Turchia 28
MX - Messico 26
ZA - Sudafrica 26
EC - Ecuador 25
PL - Polonia 25
CZ - Repubblica Ceca 22
IQ - Iraq 20
CH - Svizzera 16
NL - Olanda 16
ES - Italia 15
BE - Belgio 14
JP - Giappone 14
PK - Pakistan 14
AT - Austria 13
UZ - Uzbekistan 13
GR - Grecia 12
PH - Filippine 12
VE - Venezuela 12
JM - Giamaica 11
SA - Arabia Saudita 11
CI - Costa d'Avorio 10
CR - Costa Rica 10
ID - Indonesia 9
LB - Libano 9
CL - Cile 8
KE - Kenya 8
PE - Perù 8
AZ - Azerbaigian 7
CW - ???statistics.table.value.countryCode.CW??? 7
JO - Giordania 7
TN - Tunisia 7
TT - Trinidad e Tobago 7
EE - Estonia 6
EG - Egitto 6
GT - Guatemala 6
IL - Israele 6
MY - Malesia 6
BO - Bolivia 5
HN - Honduras 5
LT - Lituania 5
MA - Marocco 5
PS - Palestinian Territory 5
PY - Paraguay 5
SV - El Salvador 5
AE - Emirati Arabi Uniti 4
ET - Etiopia 4
NI - Nicaragua 4
EU - Europa 3
KZ - Kazakistan 3
LC - Santa Lucia 3
PA - Panama 3
RS - Serbia 3
UY - Uruguay 3
AU - Australia 2
DO - Repubblica Dominicana 2
GP - Guadalupe 2
LK - Sri Lanka 2
LR - Liberia 2
LV - Lettonia 2
MN - Mongolia 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
SC - Seychelles 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CU - Cuba 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
Totale 10.411
Salva come PNG Salva come JPEG
Città #
Singapore 920
Chandler 494
Dublin 440
San Jose 303
Hong Kong 292
Ashburn 278
San Mateo 271
Jacksonville 252
Santa Clara 169
Boardman 165
Council Bluffs 119
Dong Ket 116
Altamura 114
Princeton 109
Medford 108
Des Moines 104
Moscow 95
Wilmington 93
Lauterbourg 92
Beijing 86
Lawrence 86
Ann Arbor 72
Perugia 70
Seoul 69
Munich 67
Andover 62
Ho Chi Minh City 51
New York 51
Falls Church 47
São Paulo 47
Los Angeles 43
The Dalles 38
Saint Petersburg 36
Hanoi 35
Dallas 28
Turku 28
Norwalk 27
Dearborn 26
Piscataway 26
Woodbridge 23
North Bergen 20
Orem 20
Chennai 19
Frankfurt am Main 19
San Paolo di Civitate 19
Brooklyn 18
Milan 18
Chicago 17
Johannesburg 15
Warsaw 15
Brussels 14
Brno 13
Helsinki 13
Montreal 13
Naples 13
Phoenix 13
Shanghai 13
Atlanta 12
Houston 12
Nuremberg 12
Tokyo 12
Medellín 11
Toronto 11
Abidjan 10
Boston 10
Columbus 10
Guayaquil 10
Haiphong 10
Rome 10
Baghdad 9
Denver 9
Fremont 9
Mexico City 9
Mumbai 9
Philadelphia 9
Bogotá 8
London 8
Nairobi 8
Rio de Janeiro 8
San José 8
Buffalo 7
Cambridge 7
Fortaleza 7
Izmir 7
Manchester 7
Turin 7
Willemstad 7
Amman 6
Ankara 6
Belo Horizonte 6
Charlotte 6
Den Haag 6
Jinan 6
Kingston 6
Nagpur 6
Olomouc 6
Poplar 6
San Diego 6
San Francisco 6
Amsterdam 5
Totale 6.174
Salva come PNG Salva come JPEG
Nome #
Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice. 175
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy 159
A retroviral peptide encoded by mutated env p15E gene is recognized by specific CD8+ T lymphocytes on drug-treated murine mastocytoma P815. 159
3H-aniracetam binds to specific recognition sites in brain membranes 156
Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. 156
CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide 151
T cell apoptosis by kynurenines. 147
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. 141
Immunogenic tumor variants induced by drug treatment of the L5178Y lymphoma: search for serologically defined antigens at the clonal level. 138
Cell-mediated immunity to chemically xenogenized tumors--IV. Production of lymphokine activity by, and in response to, highly immunogenic cells. 134
Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells. 133
CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice 130
Dual effect of IL-4 on resistance to systemic gram-negative infection and production on TNF-alfa 130
T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. 129
Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis. 127
Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. 127
CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig. 126
Antilymphoma graft responses in the mouse brain: a study of T-dependent functions. 124
IL-12 acts selectively on CD8a- dendritic cells to enhance presentation of a tumor peptide in vivo 122
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells 122
Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug-treatment in vivo. 122
Antigenic changes related to drug action. 122
Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation 118
Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. 118
Antitumor activity of three nitrosourea analogues in different experimental tumor system 117
A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state 116
Towards the identification of a tolerogenic signature in IDO-competent dendritic cells 116
Modulation of tryptophan catabolism by regulatory T cells 114
CD40 ligand and CTLA-4 are reciprocally regulated in the Th1 cell proliferative response sustained by CD8+ dendritic cells. 114
Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. 111
Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. 111
Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. 110
Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. 109
IL-12 induces SDS-stable class II (alpha beta) dimers in murine dendritic cells 109
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease 109
T cell apoptosis by tryptophan catabolism 108
IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. 107
Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma 106
Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12 106
A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice 106
CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells 106
CTLA-4-Ig regulates tryptophan catabolism in vivo. 104
[In vitro cytolysis mediated by NK effectors: modification of the susceptibility of the target cell by in vivo treatment with DTIC]. 104
Cell-mediated immunity to chemically xenogenized tumors--III. Generation of monoclonal antibodies interfering with reactivity to novel antigens. 104
Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine 103
IL-23 neutralization protects mice from Gram-negative endotoxic shock. 103
Cell-mediated immunity to chemically xenogenized tumors. II. Evidence for accessory function and self-antigen presentation by a highly immunogenic tumor variant. 101
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. 100
Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia. 99
Indoleamine 2,3-dioxygenase, transcriptional regulation and autoimmunity. 98
Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization. 97
Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. 96
Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement 96
IL-12 ACTS DIRECTLY ON DC TO PROMOTE NUCLEAR LOCALIZATION OF NF-kB AND PRIMES DC FOR IL-12 PRODUCTION 96
Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity 95
IL-9 protects mice from Fram-negative bacterial shock: suppression of alfa-TNF, IL-12 and gamma-IFN, and induction of IL-10. 95
Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. 95
In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo. 95
IL-23 and IL-12 have overlapping but distinct effects on murine dendritic cells. 94
Cell-mediated immunity to chemically xenogenized tumors. V. Failure of novel antigens to increase the frequency of tumor-specific cytotoxic T cells. 93
Tryptophan catabolism generates autoimmune-preventive regulatory T cells 91
Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain. 90
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells 90
Immunogenic properties of retroviral protein p15E from drug-treated murine mastocytoma P815 88
Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex 88
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis 88
Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. 87
DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives. 87
Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. 87
Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. 86
Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant. 86
Rational bases of cancer immunochemotherapy: drug effects on antigen expression 86
IDO mediates TLR9-driven protection from experimental autoimmune diabetes 85
Endogenous retroviral gp70 genes of the murine lymphoma L5178Y: analysis of restriction fragment polymorphism upon induction of drug-mediated immunogenicity. 85
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation 84
Cell-mediated immunity to chemically xenogenized tumors--VI. The effect of cell treatment with retroviral env antisense oligonucleotides. 84
Tumor-specific L3T4+ and Lyt-2+ lymphocytes in mice primed to mutagenized cell variants. 83
IL-12 is both required and sufficient for initiating T-cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells 82
Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. 81
Cell-mediated immunity to chemically xenogenized tumors. II. Evidence for accessory function and self-antigen presentation by a highly immunogenic tumor variant. 79
Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative. 79
Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. 79
Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo. 78
T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. 78
Susceptibility of murine lymphoma cells treated with 5-(3,3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide to NK-mediated cytotoxicity in vitro. 77
Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. 77
Cytokines and tumours: problems and perspectives. 76
Induction of tumor suppression and delayed-type footpad reaction by transfer of lymphocytes sensitized to a xenogenized tumor variant. 74
O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. 74
Chemical xenogenization of tumor cells. 73
Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. 73
Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines. 72
Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens. 71
Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo. 70
Immune system to brain signaling and vice versa: The role of tryptophan and glutamate 69
Tryptophan catabolism in nonobese diabetic mice. 69
Regulation of tumor antigen expression by drugs acting as mutagens and/or gene activators. 67
Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone 67
Molecular and genomic aspects of xenogenizing-alkylating drugs. 66
I Chemioterapici 62
Totale 10.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.683
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.683
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022769 0 0 0 56 73 27 16 302 18 29 74 174
2022/20231.664 128 295 15 124 145 247 1 87 556 5 47 14
2023/2024509 44 88 19 6 3 2 108 7 65 8 71 88
2024/20251.357 21 125 77 42 195 61 11 81 265 91 252 136
2025/20263.111 197 258 166 403 354 272 557 213 320 264 74 33
2026/2027993 74 86 218 615 0 0 0 0 0 0 0 0
Totale 10.616